CorroHealth Makes Strategic Investment in Gulf Capital's SANTECHTURE, Infusing CorroHealth AI Capabilities into SANTECHTURE RCM Products Throughout GCC Region
Gulf Capital, one of the largest private equity firms investing from the GCC to the rest of Asia, announced today that global healthcare technology company CorroHealth has made a strategic investment into one of its portfolio companies, Santechture, a Dubai based pioneering revenue cycle management (RCM) intelligent technology solutions provider.The deal brings together the industry-leading AI capabilities of CorroHealth with the advanced RCM solutions of SANTECHTURE, equipping SANTECHTURE healthcare clients across the Gulf Cooperation Council (GCC) region with powerful new technology to maximize ROI.The investment formalizes what has been a productive working relationship between the two companies. Over the past two years, CorroHealth and SANTECHTURE have successfully completed multiple proofs of concept for SANTCEHTURE clients. In January, SANTECHTURE and CorroHealth jointly hosted the Arab Health reception focused on AI and Revenue Cycle Management (RCM) Innovation.SANTECHTURE, which is backed by leading institutional investors Gulf Capital and Shorooq Partners, has seen a phenomenal increase in demand for its advanced deep tech RCM solutions in the GGC and across regional markets, and this partnership will support yet another leap ahead in advancing innovation and value creation.CorroHealth CEO Pat Leonard said, 'This is an exciting step forward for CorroHealth, as we combine our technological capabilities with a local company based in the GCC region. CorroHealth joining forces with SANTECHTURE brings the best of both worlds to provide clients in the region with unsurpassed RCM capabilities to protect hospitals' bottom lines and help to ensure their financial future.'SANTECHTURE Founder and CEO Anas Batikhi said, 'The pairing of SANTECHTURE's unique leading-edge solutions with CorroHealth's AI driven innovations in the RCM technology space is truly unrivalled. We are especially thrilled to be cementing further our working relationship with CorroHealth and leading the intelligent automation drive to support our clients and partners with their RCM digital transformation journey, delivering on cost reduction and improved revenue outcomes.'Gulf Capital Managing Director Mohammad Madani added, 'We are proud to have been early backers of SANTECHTURE and to now support this landmark partnership between SANTECHTURE's and CorroHealth. This strategic investment is a strong validation of SANTECHTURE's leadership in intelligent RCM solutions across the GCC and marks a pivotal milestone in its growth journey. We are confident this collaboration will unlock significant value for healthcare providers in the region.'
Bilal Mushtaq, MD, CorroHealth's Executive Vice President of Global Growth and Strategy for GCC market expansion said 'This strategic investment and partnership marks a pivotal step forward in our growth strategy, reinforcing our commitment to innovation and delivering greater value to a new market. This is not just a collaboration but a shared vision to forge a new path towards providing excellence in revenue cycle management.'
© 2000 - 2025 Al Bawaba (www.albawaba.com)
Signal PressWire is the world's largest independent Middle East PR distribution service.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Bawaba
3 hours ago
- Al Bawaba
China's Center for Drug Evaluation Accepts Merck's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company's application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in May for the treatment of patients with TGCT who require systemic therapy, which is expected to expedite the review process. Pimicotinib, a potentially best-in-class investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., also has been granted breakthrough therapy designation (BTD) by the NMPA. 'With the acceptance of our application for pimicotinib and the initiation of the priority review, we aim to offer patients in China the first approved systemic therapy for TGCT, addressing a tremendous unmet need in this country,' said Hong Chow, Head of China and International, Healthcare business of Merck. 'Pimicotinib has demonstrated the ability to not only shrink tumors that affect their joints but also improve outcomes like mobility, pain and stiffness, highlighting its potential to be a best-in-class treatment for TGCT. In parallel, we are working to file a New Drug Application to the US Food and Drug Administration, with additional filings planned in other markets.' TGCT is a locally aggressive and often recurring tumor of the joints that can cause high morbidity associated with swelling, pain, stiffness, and limited mobility of the affected joints, significantly impacting daily activities and quality of life in the primarily working-age population that it affects. If left untreated or in recurrent cases, TGCT can result in irreversible damage to the bone, joint and surrounding tissues. This highlights the need for well-tolerated and effective systemic treatments that can impact tumor growth while relieving the symptoms of the disease. The application is based on results from Part 1 of the global Phase 3 MANEUVER study, in which once-daily pimicotinib demonstrated a statistically significant improvement in the primary endpoint of objective response rate (ORR) assessed by blinded independent review committee (BIRC) compared with placebo at week 25 (54.0% vs. 3.2% for placebo; p<0.0001). The study also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain. The data were presented earlier this month at the 2025 ASCO Annual Meeting.
Al Bawaba
3 hours ago
- Al Bawaba
Deutsche Bank and Ant International Announce Strategic Partnership to Provide Integrated Cross-Border Payment Solutions to Global Merchants
Deutsche Bank and Ant International have announced their strategic partnership to provide more comprehensive payment solutions for businesses of all sizes in Europe and Asia, by combining their expertise and leveraging Ant International's proprietary tokenisation and AI-based FX bank will collaborate with Ant International's Embedded Finance unit on a series of global treasury management and cross-border payment innovations, including tokenised deposits, stablecoin, and its Time-Series Transformer (TST) FX Bank will be the first German bank to facilitate Ant International's blockchain-based real-time treasury management platform to enable real-time fund transfers between Ant International's intragroup entities. This will enable more efficient and transparent global treasury management for addition, the two sides will also explore cross-border payment innovations, including tokenised bank deposits, stablecoin and Ant International's Falcon TST FX Model, to help Ant International and its clients reduce FX-related cost and risks. Both companies will also further look into the applications of stablecoins for global payments, including real-time cross-border treasury management for Ant's entities, reserve management and on-ramp and off-ramp Bank will also work with Antom, a merchant payment and digitisation services provider, to scale up their collaboration to extend Antom's acquiring solutions for merchants in EMEA, enabling them to be seamlessly integrated with more payment bank will also support WorldFirst's suite of payments-related solutions for SMEs in e-commerce and cross-border trade, including but not limited to account collections, payments and FX services. It will also enable the account and financial service provider to access its global network to serve its Matthiessen, Head of Corporate Bank APAC & MEA and Global Head of Cash Management for Deutsche Bank, said: 'We are delighted to strategically cooperate with Ant International. We will leverage our broad product capabilities and strong global network to deliver seamless and secure payment solutions to Ant International and its customers in Europe and Asia. Given the dynamic landscape of financial services, we see great potential to collaborate with Ant International, as one of the world's leading financial technology providers, to develop innovative payment solutions and transform the future of treasury management.'Kelvin Li, General Manager of Platform Tech at Ant International, said: 'With a dynamic fintech landscape, Europe is fast-becoming a key hub for global digital payment innovation. We are pleased to deepen our commitment to the region through this collaboration with Deutsche Bank, supporting the development of more seamless, secure and inclusive cross border payment solutions. By combining our digital and payment capabilities with a global leading financial institution, we aim to deliver enhanced payment experiences that meet the evolving needs of global businesses and consumers.' Expanding on a client relationship that has been in place since 2019, the two sides signed a Memorandum of Understanding (MoU) on June 8 in Munich, Germany to deepen the strategic collaboration.
Al Bawaba
17 hours ago
- Al Bawaba
Emaar Properties Launches VYOM
Emaar Properties proudly announces the launch of VYOM, a groundbreaking digital resale platform set to redefine the way Emaar homes are bought and sold. Purpose-built for today's discerning homeowners and investors, VYOM offers a seamless, end-to-end experience that is transparent, secure, and powered by the innovation and trust that define VYOM, users gain complete control over the resale process—creating listings, uploading property images, and managing inquiries directly—all within an intuitive interface. This is a transformative step in Emaar's ongoing digital evolution, offering a smarter, frictionless alternative to traditional resale methods.'As the real estate landscape shifts, so must we. VYOM is more than a platform—it's a new way of thinking about property resale. It puts autonomy, trust, and speed into the hands of our customers,' said Mohamed Ali Alabbar, Founder of Dubai's real estate market continues its dynamic growth, VYOM tackles long-standing inefficiencies such as pricing discrepancies, market opacity, and communication gaps. The platform enhances transparency and facilitates direct engagement between buyers and sellers—fostering fair, informed transactions. Now live and accessible globally, VYOM marks a bold new chapter in Emaar's commitment to delivering customer-first solutions across the full property ownership journey—from purchase to resale, and soon, to rental.
